Scancell Share Discussion Threads

[emptyend] 19/5/2021 21:38

Interesting development:https://cepi.net/news_cepi/cepi-expands-global-footprint-of-its-covid-19-vaccine-lab-network-and-opens-testing-against-variants-of-concern/.....I'd guess we know one of the 20?

[emptyend] 19/5/2021 13:00

Correct me if I'm wrong, but there are still nearly 6 weeks left of Q2.Of course further delays are possible, but IMO these will be CEPI-related if they occur.As one who has sat on the board of a company with a news-driven share price, I can empathise with Holloway. Not all of the elements here are under the control of the company.....the pandemic itself has consequences (eg. new variants = more lab testing) but there are also powerful political issues, including those related to CEPI, GAVI etc.In such circumstances, it is virtually impossible to provide reliable guidance on timing, so managements generally indicate timings that are achievable PROVIDING THAT third parties don't throw more spanners in the works. That, unfortunately, can never be guaranteed.....

[gooosed] 19/5/2021 12:37

Scancell retweet :



"Experts suggest that developing a universal coronavirus vaccine is not only possible, but could be realised in the coming years. Bette Browne reports"

Seems like an appropriate timeline for Scancell - given it's history....none of the Q4 2020, Q1 2021 or Q2 2021 as Holloway RNS'd - now sometime H2 2021. Bets on yet another push back from there.....

Management of expectations via Twitter & it wasn't that long ago that someone ventured that Holloway had nowhere to hide.

[emptyend] 19/5/2021 12:28

....interesting, given that Scancell were name-checked in this tweet, which they have just retweeted....https://twitter.com/med_indonews/status/1394971554472243200?s=21I continue to wait for CEPI news......

[888icb] 19/5/2021 11:43

Ticking up on virtually every trade now. Up 4.9% on volume of 129000 from 13 trades.

[torquayfan] 19/5/2021 09:36

"A new study conducted by a team of U.S. scientists has found that the COVID-19 vaccines developed by Pfizer (PFE +0.1%)/BioNTech (BNTX -2.1%) and Moderna (MRNA +0.7%) remain effective against the coronavirus variants first detected in India.
"What we found is that the vaccine's antibodies are a little bit weaker against the variants, but not enough that we think it would have much of an effect on the protective ability of the vaccines," senior author Nathaniel "Ned" Landau has told AFP."

[oldnotwise] 19/5/2021 08:00

20.45/20.92

[panama7] 18/5/2021 14:01

Super that article is as corrupt as the WHO. Real Critical Care Doctors treating real Patients have saved thousands of lives FACT. Judges in New York have forced Medical Practices to issue Ivermectin at the request of families. all elderly patients fully recovered.

[marcusl2] 18/5/2021 13:59

in late preclinical development

Agenus will receive a $200 million upfront payment and up to $1.36 billion in development, regulatory and commercial milestones in addition to tiered double-digit royalties on net product sales.

AGEN1777 is an Fc-enhanced antibody in late preclinical development designed to target major inhibitory receptors expressed on T and NK cells to improve anti-tumor activity. In preclinical studies this approach has shown significant potential in tumor models where anti-PD-1 or anti-TIGIT monospecific antibodies alone are ineffective.

Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody Program
Agenus to receive a $200 million upfront payment and up to $1.36 billion in milestone payments
May 18, 2021 07:30 ET | Source: Agenus Inc.




...
NEW YORK and LEXINGTON, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- Bristol-Myers Squibb Company (NYSE: BMY) and Agenus Inc. (NASDAQ: AGEN) today announced that they have entered into a definitive agreement under which Bristol Myers Squibb will be granted a global exclusive license to Agenus’ proprietary bispecific antibody program, AGEN1777, that blocks TIGIT and a second undisclosed target. AGEN1777 is an Fc-enhanced antibody in late preclinical development designed to target major inhibitory receptors expressed on T and NK cells to improve anti-tumor activity. In preclinical studies this approach has shown significant potential in tumor models where anti-PD-1 or anti-TIGIT monospecific antibodies alone are ineffective.

Under the agreement, Bristol Myers Squibb will become solely responsible for the development and any subsequent commercialization of AGEN1777 and its related products worldwide. Agenus will receive a $200 million upfront payment and up to $1.36 billion in development, regulatory and commercial milestones in addition to tiered double-digit royalties on net product sales. Agenus will retain options to conduct clinical studies under the development plan, to conduct combination studies with certain other Agenus pipeline assets, and also, upon commercialization, to co-promote AGEN1777 in the US. The agreement is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

Agenus expects to file an Investigational New Drug (“IND”) application for the development of AGEN1777 with the U.S. Food and Drug Administration in the second quarter of 2021. Bristol Myers Squibb intends to advance the research and development of AGEN1777 in immuno-oncology (“I-O”) for high priority tumor indications including non-small cell lung cancer.

“AGEN1777̵7;s differentiated mechanism of action provides the potential for potent anti-tumor activity; catalyzing our clinical TIGIT strategy aimed at serving more patients with unmet needs in cancer,” said Debbie Law, D.Phil., Senior Vice President, Head of Tumor Microenvironment Thematic Research Center, Bristol Myers Squibb. “We look forward to working with Agenus to develop this important therapy as we continue to combat I-O resistance.”

“We are pleased to partner with Bristol Myers Squibb to develop and commercialize AGEN1777. Their stellar record of success in this area has been an important determinant for our decision to enter into this transaction,” said Garo Armen, PhD, Chairman and Chief Executive Officer of Agenus. “Through such transactions we are able to balance between advancing our portfolio with highly qualified collaborators, while retaining our other innovations for speedy development and commercialization by Agenus.”

About AGEN1777

AGEN1777 is a potentially first-in-class bispecific anti-TIGIT antibody engineered with an enhanced Fc region for high binding affinity and improved T and NK cell activation.

[supernumerary] 18/5/2021 11:23

Interesting research on ivermectin just published:



Abstract
Antiviral therapies are urgently needed to treat and limit the development of severe COVID-19 disease. Ivermectin, a broad-spectrum anti-parasitic agent, has been shown to have anti-SARS-CoV-2 activity in Vero cells at a concentration of 5 micromolar. These in vitro results triggered the investigation of ivermectin as a treatment option to alleviate COVID-19 disease. In April 2021, the World Health Organization stated, however, the following: "the current evidence on the use of ivermectin to treat COVID-19 patients is inconclusive". It is speculated that the in vivo concentration of ivermectin is too low to exert a strong antiviral effect.

Here, we performed a head-to head comparison of the antiviral activity of ivermectin and a structurally related, but metabolically more stable, moxidectin in multiple in vitro models of SARS-CoV-2 infection, including physiologically relevant human respiratory epithelial cells. Both moxidectin and ivermectin exhibited antiviral activity in Vero E6 cells. Subsequent experiments revealed that the compounds predominantly act on a step after virus cell entry.

Surprisingly, however, in human airway-derived cell models, moxidectin and ivermectin failed to inhibit SARS-CoV-2 infection, even at a concentration of 10 micromolar. These disappointing results calls for a word of caution in the interpretation of anti-SARS-CoV-2 activity of drugs solely based on Vero cells. Altogether, these findings suggest that, even by using a high-dose regimen of ivermectin or switching to another drug in the same class are unlikely to be useful for treatment against SARS-CoV-2 in humans.

[torquayfan] 18/5/2021 10:30

Ivy I'm guessing the Indy piece was triggered by an update from the 'Duke Human Vaccine Institute' on their project and the Scancell section was to pad it out. Never mind - good to see anyway. But nothing new. News please . . .

[ivyspivey] 18/5/2021 08:15

Morning TF.You are right that it is 100%. I can also confirm that the comments attributed to Gillies were from some time ago.

[oldnotwise] 18/5/2021 08:00

20.05/20.3

[torquayfan] 18/5/2021 03:46

Ivy 39251. Re. Covidity and a 99.999% certainty being a DNA vaccine. 100% even ?

With respect I gave you the wrong end of the stick when I referred to Crumb's post which had the original comment with a wink insignia.

Re. mRNA vaccines and Patents etc. I wonder what the same network analysis of Scancell's (DNA) Covidity vaccine would look like - a lot more simple I hope . . .

[emptyend] 17/5/2021 17:14

I'd be unsurprised if Vulpes had added today....

[sicilian_kan] 17/5/2021 17:11

I added about an extra 10% to my holding today too.

[peanut100] 17/5/2021 17:09

Started adding today at 20p, looks like with today's volume seller cleared and were very bid this afternoon. Lucky to buy them lower than Friday after yesterday's article.

[emptyend] 17/5/2021 15:44

Patience is a virtue....... ;-)